

IN THE SPECIFICATION

Please amend the text as follows:

On page 5, lines 30-31.

Figure 3 is a schematic representation of β -synuclein (Seq ID 11), β -synuclein mutants ($\delta 1$ (Seq ID 12) and $\delta 2$ (Seq ID 13)), and NACP/ α -synuclein (Seq ID 14).

On page 6, lines 11-23.

Figures 7a-f illustrate the characterization of NACP/ α -synuclein expression in human α -synuclein transgenic mice, where Figure 7a provides the construct of the human PDGF β promoter driven encoding human α -synuclein; Figure 7b shows α -synuclein mRNA levels in brain tissues from non-transgenic and transgenic mice and from humans with neurological disease; Figure 7c illustrates a bar graph of the PhosphorImager analysis of human α -synuclein mRNA expressed as a percentage of the human control; Figure 7d illustrates a comparison of human (Seq ID 15) and murine (Seq ID 16) NACP/ α -synuclein sequences; Figure 7e shows the Western blot analysis showing affinity-purified human- and mouse-specific α -synuclein antibodies; and Figure 7f shows the PhosphorImager analysis of human α -synuclein signals from semi-quantitative Western blots of human α -synuclein expression in the different transgenic lines.

[PA9013.AMDYMASL04.B02.frm]

7. (twice amended) The method of claim 4, wherein the treatment comprises expression of a non-amyloidogenic protein that modulates aggregation of NACP/ α -

[PA9013.AMDYMASL04.B02.frm]